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OBJECTIVE: The purpose of this study was to under-
stand the decision-making process used when selecting
ulcer-dressing products, and to ascertain the use of health
economics in the decision process.
METHODS: Diverse groups of nurses highly involved in
product selection were interviewed. The groups included
five home-care nurses (Group 1), four acute-care nurses
(Group 2), and five nurses who spent some time in LTC
(Group 3). Discussions centered on 1) product switching
triggering events, 2) key decision-makers, 3) mapping the
decision-making process, and 4) understanding of health
economics. Information about the key decision-makers at
different institutions was discussed.
RESULTS: 1) Performance issues were the most common
reasons for product switching (66%). Product availabil-
ity was the most influential factor (48%). 2) No differ-
ences in product selection criteria were observed among
nurses in home, acute and long-term care. However, level
and role of the nurse in each setting influenced his or her
part in decision-making and product selection. 3) Product
evaluation and hands-on experience were the most im-
portant elements for selecting a new or replacement
product. The ability to incorporate the product into cus-
tomized patient protocols was also important. 4) While
nurses were somewhat familiar with the term “cost-effec-
tiveness,” most preferred the term “value.” Approxi-
mately half used such information to support wound-care
product decisions. Nurses were more likely to consider a
product supported by a straightforward economic assess-
ment rather than a complex decision analysis.
CONCLUSION: Product selection relies heavily on trial
evaluations. In addition, published health-economic stud-
ies are often too complicated. In order for health-eco-
nomics research to inform decision-making in the wound-
care market, studies should: 1) identify target audiences
and address their decision-making needs; 2) “speak” to
their audience by using terms familiar to decision-mak-
ers; and 3) present simplified diagrams, charts or models.
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OBJECTIVE:
 
 Canadian provinces have different policies
on the reimbursement of proton pump inhibitors (PPIs)
(Quebec open, Ontario restricted). This study examined
the effect of these policies on the use of PPI and H2-recep-
tor antagonists (H2RA), one-year gastrointestinal (GI) re-
source utilization and costs.
METHODS: Merged provincial databases from Quebec
and Ontario were analyzed for new users of PPIs and
H2RAs aged 66 or greater who began treatment between
November 1, 1996 to October 31, 1997. GI related ser-
vices and costs (GI drugs, physician visits, GI procedures
and hospitalizations) were analyzed using multivariate
regression equations on an intent-to-treat basis.
RESULTS: 82,314 Ontario and 19,719 (50% sample)
Quebec patients were identified as new GI drug users.
The patients were similar in age, gender and length of fol-
low-up. At the initial visit, 12.5% of Ontario and 24.1%
of Quebec patients were prescribed PPIs, and 63.7% of
Ontario and 50.0% of Quebec patients were prescribed
H2RAs. GI hospitalization occurred in 1.7% of Ontario
and 1.4% of Quebec patients (p  .01). Endoscopy rate
for Ontario was 4.7% and 9.1% for Quebec (p  .001);
upper GI radiography rate was 13.8% for Ontario and
9.9% for Quebec (p  .01). Factors related to PPI versus
H2RA prescription included residence in Quebec (OR
2.3), initial prescription by GI specialist (OR 4.1), other
specialist (OR 1.9) and endoscopy (OR 1.9).
CONCLUSION: Restrictive drug policy influenced both
drug and other resource utilization. In both provinces,
PPI use was associated with increased disease severity
and resource utilization.
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OBJECTIVES:
 
 To develop a macro-economic model to
assist European policy makers in assessing the effects of
different measures to reduce problematic drug use.
METHODS: Existing economic behavior theories and
different modalities of heroin use provided a number of
principles and a framework out of which a cohort-level
macro-economic model was created. A 20-year, Markov
state-transition model was developed, within which a
(potential) cohort of the adult general population makes
